The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy
Open accessAbstract
Lenalidomide combined with dexamethasone is an effective treatment for refractory/relapsed multiple myeloma (MM). Lenalidomide stimulates natural killer (NK) cells and enhances antitumor responses. We assessed NK cell number and function in 25 patients with MM participating in a clinical trial of lenalidomide and dexamethasone. NK cell numbers increased from a mean of 2.20 ± 0.05 × 105/mL (baseline) to a mean of 3.90 ± 0.03 × 105/mL (cycle 6; P = .05); however, in vitro NK-cell–mediated cytotoxicity decreased from 48.9% ± 6.8% to 27.6% ± 5.1% (P = .0028) and could not be rescued by lenalidomide retreatment. Lenalidomide increased normal donor NK-cell cytotoxicity in vitro from 38.5% to 53.3%, but this was completely abrogated by dexamethasone. Dexamethasone suppression of NK cell–mediated cytotoxicity was partially reversed by a 3-day washout, but these cells remained refractory to lenalidomide-induced enhanced function. Lymphocyte subset depletion experiments revealed that lenalidomide's enhancement of NK cell–mediated cytotoxicity was mediated by CD4+ T-cell production of interleukin 2 and that dexamethasone acted by suppressing interleukin-2 production. Similarly, the reduced ability of NK cells from patients with MM to respond to lenalidomide was also due to impaired CD4 T-cell function. Our findings indicate that lenalidomide immunostimulatory effects on patient NK cells are severely blunted by concurrent dexamethasone administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citation
Cited by
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Natural killer cell biology: An update and future directions
Campbell, K. S., & Hasegawa, J. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.006 · Cited by 416
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 255
Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00283-0 · Cited by 212
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs
D'Souza, C., Prince, H. M., & Neeson, P. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632399 · Cited by 52
Self-citation
Metadata
- Authors
- Hsu, A. K., Quach, H., Tai, T., Prince, H. M., Harrison, S. J., Trapani, J. A., Smyth, M. J., Neeson, P., & Ritchie, D. S.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-02-03
- Volume
- 117
- Issue
- 5
- Pages
- 1605-1613
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1969848086
- Cited by
- 158
- References
- 2
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. https://app.cochat.ai/papers/10.1182/blood-2010-04-278432
- The paper
- Hsu, A. K., Quach, H., Tai, T., Prince, H. M., Harrison, S. J., Trapani, J. A., Smyth, M. J., Neeson, P., & Ritchie, D. S. (2011). The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. https://doi.org/10.1182/blood-2010-04-278432
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.